

Health Library
October 10, 2025
Question on this topic? Get an instant answer from August.
I-Brentuximab iyimithi yomdlavuza eqondiwe esiza ukulwa nezinhlobo ezithile zomdlavuza wegazi, ikakhulukazi ama-lymphomas. Yilokho odokotela abakubiza ngokuthi "i-monoclonal antibody-drug conjugate," okusho ukuthi ihlanganisa iphrotheni etholakala kumaseli omdlavuza ngemithi ye-chemotherapy eyawabulala. Le mithi inikezwa nge-IV infusion ehhovisi likadokotela wakho noma esibhedlela, futhi yenzelwe ukuthi iqondise ngqo amaseli omdlavuza ngenkathi ishiya amaseli anempilo evikelekile.
I-Brentuximab yindlela ekhethekile yokwelapha umdlavuza esebenza njenge-guided missile ngokumelene nezinhlobo ezithile zomdlavuza wegazi. Imithi ihlanganisa izingxenye ezimbili ezinamandla: i-antibody efuna amaprotheni athile kumaseli omdlavuza, kanye nomuthi we-chemotherapy olethwa ngqo kulawo maseli. Le ndlela eqondiwe isiza umuthi ukuthi usebenze ngempumelelo kakhulu ngenkathi kungenzeka ukuthi ibangela imiphumela emibi embalwa kune-chemotherapy yendabuko.
Umuthi uqondise ngqo iphrotheni ebizwa nge-CD30, etholakala ebusweni bamaseli athile omdlavuza. Lapho i-brentuximab ithola la maseli, inamathela kuwo futhi ikhiphe i-chemotherapy yayo ngqo ngaphakathi kweseli lomdlavuza. Lokhu kuqondisa okunembile yikho okwenza i-brentuximab ihluke ekwelashweni komdlavuza okudala okuthinta amaseli anempilo nawomdlavuza.
I-Brentuximab isetshenziselwa ikakhulukazi ukwelapha izinhlobo ezithile ze-lymphoma, okuyizinhlobo zomdlavuza ezithinta uhlelo lwakho lwe-lymphatic. Udokotela wakho angase akwelule ukuthi usebenzise le mithi uma une-Hodgkin lymphoma noma izinhlobo ezithile ze-T-cell lymphomas eziphinde zabuya ngemva kokwelashwa noma ezingaphendulanga kwezinye izindlela zokwelapha.
Umuthi uvame ukusetshenziswa lapho ezinye izindlela zokwelapha zingasebenzi kahle njengoba bekulindelekile, noma lapho umdlavuza ubuyela ngemva kokuxolelwa. Ngezinye izikhathi odokotela basebenzisa i-brentuximab njengengxenye yohlelo lokwelapha oluhlanganisiwe, besebenza kanye neminye imithi yomdlavuza ukukunikeza umphumela ongcono kakhulu. Udokotela wakho we-oncologist uzoqaphela ukuthi uhlobo lwakho oluthile lwe-lymphoma lunamaprotheni e-CD30 enza i-brentuximab isebenze.
I-Brentuximab isebenza njengomuthi womdlavuza oqondiswe ngokuqinile, olungcono kunamakhemikhali endabuko. Cabanga ngayo njengohlelo lokuletha oluthwala amakhemikhali ngqo emangqamuzaneni omdlavuza ngenkathi igcina izicubu ezinempilo. Umuthi uhamba ngomgudu wakho wegazi uze uthole amangqamuzana anamaprotheni e-CD30 ebusweni bawo.
Lapho i-brentuximab inamathisela emangqamuzaneni omdlavuza, ingena ngaphakathi lapho ikhipha khona umuthi onamandla wamakhemikhali obizwa ngokuthi i-monomethyl auristatin E (MMAE). Lo muthi ube uselimala ikhono lamangqamuzana omdlavuza lokuhlukanisa nokukhula, ekugcineni kuholele ekufeni kweseli. Ngenxa yokuthi amakhemikhali alethwa ngqo emangqamuzaneni omdlavuza, ungase uthole imiphumela emincane ebanzi yezinhlangothi ezivamile zamakhemikhali endabuko.
I-Brentuximab inikezwa njenge-intravenous (IV) infusion, okusho ukuthi ilethwa ngqo emgudwini wakho wegazi ngomthambo. Uzothola lokhu kwelashwa ehhovisi likadokotela wakho, emtholampilo ongaguli ngaphandle, noma esibhedlela, futhi inqubo ngokuvamile ithatha imizuzu engaba ngu-30. Umuthi uvame ukunikezwa kanye njalo emavikini amathathu, nakuba udokotela wakho ezoqaphela isimiso esiqondile esisekelwe esimweni sakho esithile.
Ngaphambi kokufakwa kwakho, akudingeki ukuthi ugweme ukudla noma ukuphuza, kodwa kuyasiza ukuhlala unamanzi kahle futhi udle ukudla okulula ngaphambi kwalokho. Ithimba lakho lezempilo lizokuqapha ngesikhathi nangemva kokufakwa ukuze libheke noma yiziphi izindlela zokuphendula ngokushesha. Ungase uzizwe ukhululekile ngokuletha incwadi, ithebhulethi, noma eminye imisebenzi ethule ukusiza ukudlulisa isikhathi ngesikhathi sokwelashwa.
Udkt wakho angase akunikeze imithi ngaphambi kokufakwa kwakho kwe-brentuximab ukusiza ukuvimbela ukusabela komzimba noma isicanucanu. Lezi
Njengazo zonke izidakamizwa zomdlavuza, i-brentuximab ingabangela imiphumela emibi, nakuba abantu abaningi beyibekezelela kahle. Imiphumela emibi evame kakhulu ongase uyithole ngokuvamile ilawuleka ngokunakekelwa okufanele nokuqashwa ithimba lakho lezempilo.
Nawa amanye imiphumela emibi evame kakhulu abantu abaningi abayitholayo ngesikhathi sokwelashwa nge-brentuximab:
Le miphumela emibi ivamise ukuba milde kuya esimweni esiphakathi nendawo futhi ivame ukuthuthuka njengoba umzimba wakho ujwayela umuthi. Ithimba lakho lezempilo linganikeza imithi namasu okusiza ukulawula lezi zimpawu ngempumelelo.
Kukhona neminye imiphumela emibi engathi sína edinga ukunakekelwa ngokushesha, nakuba ingavamile. Lokhu kuhlanganisa ukulimala okukhulu kwemizwa okubangela ukuba ndikindiki okukhulu noma ubuthakathaka, izifo ezingathi sína ngenxa yokwehla komsebenzi wokuzivikela komzimba, kanye nesimo esingavamile kodwa esibi samaphaphu esibizwa ngokuthi i-pneumonitis. Ngaphezu kwalokho, abanye abantu bangase babe ne-tumor lysis syndrome, lapho amaseli omdlavuza ewohloka ngokushesha kangangokuthi kuthinta ukusebenza kwezinso.
Enye imiphumela emibi okufanele iqashelwe i-peripheral neuropathy, engabangela ukuluma, ukuba ndikindiki, noma ubuhlungu ezandleni nasemilenzeni yakho. Lokhu kuvame ukwenzeka nge-brentuximab kunokwelashwa komdlavuza okuthile, futhi kubalulekile ukubika noma yikuphi ukuba ndikindiki okusha noma ukuluma kudokotela wakho ngokushesha. Ezimweni eziningi, le miphumela emibi iyabuyiseka, ikakhulukazi uma itholwe kusenesikhathi.
IBrentuximab akulungele wonke umuntu, futhi udokotela wakho uzohlola ngokucophelela ukuthi ngabe yikho yini okulungele isimo sakho esithile. Abantu abanezimo ezithile zezokwelapha noma labo abathatha imithi ethile bangase badinge ukwelashwa okuhlukile noma ukuqashwa okukhethekile.
Akufanele uthole i-brentuximab uma wazi ukuthi unokungezwani okukhulu nomuthi noma yiziphi izingxenye zawo. Ngaphezu kwalokho, uma unezifo eziqhubekayo, ezingathi sína, udokotela wakho cishe uzofuna ukuzelapha kuqala ngaphambi kokuqala i-brentuximab, ngoba umuthi ungathinta ikhono lomzimba wakho lokuzivikela ekulweni nezifo.
Udokotela wakho uzoba nokuqapha okukhethekile mayelana nokunikeza i-brentuximab uma unezinkinga zemizwa ezikhona, isifo sesibindi, noma izinkinga zezinso. Abantu abanomlando wezinkinga zenhliziyo bangase badinge ukuqashwa okukhethekile, njengoba okunye ukwelashwa komdlavuza kungathinta ukusebenza kwenhliziyo. Uma ukhulelwe noma uncelisa, i-brentuximab ngokuvamile ayinconywa, ngoba ingalimaza izingane ezisakhula.
Uma ngabe uke wathola i-bleomycin (omunye umuthi womdlavuza), udokotela wakho uzohlola ngokucophelela izingozi nezinzuzo, ngoba kungase kube nengozi eyengeziwe yezinkinga zamaphaphu uma le mithi isetshenziswa ndawonye. Abantu abanezinhlelo zokuzivikela ezilimele ngenxa yezinye izimbangela bangase badinge ukucatshangelwa okukhethekile ngaphambi kokuqala ukwelashwa.
I-Brentuximab yaziwa kakhulu ngegama layo lomkhiqizo elithi Adcetris. Leli igama ozolibona kumalebula akho emithi kanye nemibhalo yomshuwalense. Igama eliphelele elivamile lithi brentuximab vedotin, elibonisa inhlanganisela ethile yomzimba wokulwa nezifo (brentuximab) kanye nomuthi we-chemotherapy (vedotin ibhekisa engxenyeni ye-monomethyl auristatin E).
Uma ukhuluma nethimba lakho lezempilo, inkampani yomshuwalense, noma usokhemisi, ungasebenzisa kokubili "Adcetris" noma "brentuximab vedotin" - bazokuqonda ukuthi ukhuluma ngomuthi ofanayo. Amanye amarekhodi ezokwelapha angasebenzisa isifinyezo esithi "BV" se-brentuximab vedotin, esivame ukusetshenziswa ezindaweni ze-oncology.
Uma i-brentuximab ingafaneleki esimweni sakho, kunezindlela eziningi zokwelapha ezingase zitholakale kuye ngohlobo lwakho oluthile lwe-lymphoma. Udokotela wakho we-oncologist uzocabangela izinto ezinjengempilo yakho yonke, ukwelashwa kwangaphambilini, kanye nezici ezithile zomdlavuza wakho lapho kuxoxwa ngezindlela zokwelapha.
Nge-Hodgkin lymphoma, ezinye izindlela zokwelapha zingabandakanya izinhlanganisela zamakhemikhali endabuko njenge-ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) noma izindlela zokwelapha ezintsha eziqondiwe njenge-nivolumab noma i-pembrolizumab, esebenza ngokusiza amasosha akho omzimba ukuthi alwe nomdlavuza. Abanye abantu bangase babe ngabazongenela ukwelashwa kwe-CAR-T cell, lapho amaseli akho omzimba aguqulwa ukuze alwe kangcono namaseli omdlavuza.
Ngezinhlobo ezithile ze-T-cell lymphomas, ezinye izinketho zingabandakanya imithi enjenge-romidepsin, belinostat, noma i-pralatrexate. Izivivinyo zemitholampilo eziphenya ngezindlela zokwelapha ezintsha eziqondiwe nazo zivame ukutholakala, futhi udokotela wakho angakusiza ukuthi uqonde ukuthi ngabe yikuphi ukwelashwa okungokwesipiliyoni okungase kufanele esimweni sakho.
Ukukhetha phakathi kwalezi zindlela kuncike ezintweni eziningi, okuhlanganisa ukuthi umdlavuza wakho usabele kanjani ekwelashweni kwangaphambilini, isimo sakho sempilo yonke, kanye nezintandokazi zakho mayelana nokuqina kokwelashwa nemiphumela emibi.
Ukuthi i-brentuximab “ingcono” kunezinye izindlela zokwelapha i-lymphoma kuncike ngokuphelele esimweni sakho esithile, uhlobo lwe-lymphoma, kanye nezici zempilo yakho. Ezinhlotsheni ezithile ze-lymphoma, ikakhulukazi lezo ezinamaseli e-CD30-positive, i-brentuximab ikhombise imiphumela emihle kakhulu futhi ingasebenza kangcono kune-chemotherapy yendabuko yodwa.
Ezifundweni zomtholampilo, i-brentuximab ikhombise amazinga aphezulu okusabela e-Hodgkin lymphoma ebuyele emuva noma e-refractory, ngokuvamile isebenza kahle ngisho nalapho ezinye izindlela zokwelapha ziye zahluleka. Uhlobo oluqondiwe lolu lwempilo futhi lisho ukuthi abantu abaningi baba nemiphumela emibi embalwa ehambisana ne-chemotherapy yendabuko, njengokucasuka okukhulu, ukulahlekelwa izinwele, noma ukwehla okukhulu ekubalweni kwegazi.
Nokho, “okungcono” kuhlale kuhlobene ekwelapheni umdlavuza. Abanye abantu basabela ngendlela emangalisayo ku-chemotherapy yendabuko futhi abadingi ukwelashwa okuqondiwe. Abanye bangazuza ezindleleni ezintsha ze-immunotherapy. Udokotela wakho we-oncologist ucabangela izici eziningi lapho encoma ukwelashwa, okuhlanganisa izici ezithile zomdlavuza wakho, impilo yakho yonke, ukwelashwa kwangaphambilini, kanye nemigomo yakho kanye nezintandokazi zakho.
Into ebaluleke kakhulu ukuthola indlela yokwelapha ekunikeza ithuba elingcono kakhulu lokulawula i-lymphoma yakho ngenkathi ugcina izinga lempilo yakho. Lokhu kuvame ukubandakanya inhlanganisela eyenziwe ngendlela oyiphilayo yezindlela zokwelapha ezihlukene kunokuncika emuthini owodwa “ongcono”.
I-Brentuximab ingasetshenziswa kubantu abanezifo zenhliziyo, kodwa idinga ukuqapha ngokucophelela nokuxhumana phakathi kukadokotela wakho we-oncologist kanye nodokotela wenhliziyo. Nakuba i-brentuximab ngokwayo ngokuvamile ingabangeli izinkinga eziqondile zenhliziyo, abanye abantu abathola ukwelashwa komdlavuza bangase babe nezinguquko ekusebenzeni kwenhliziyo, ikakhulukazi uma beke baba nezinkinga zenhliziyo ngaphambili noma bathola ezinye izindlela zokwelapha umdlavuza ezingase zithinte inhliziyo.
Udktela wakho cishe uzo-oda izivivinyo zomsebenzi wenhliziyo ngaphambi kokuqala i-brentuximab futhi angase aqaphe inhliziyo yakho ngesikhathi sokwelashwa. Uma unomlando wezinkinga zenhliziyo, qiniseka ukuthi uxoxa lokhu ngokucophelela nethimba lakho lezempilo ukuze bakwazi ukudala uhlelo lokwelapha oliphephe kakhulu kuwe.
Njengoba i-brentuximab inikezwa ochwepheshe bezempilo endaweni yezokwelapha, ukweqisa ngengozi akuvamile kakhulu. Umuthi ubalwa ngokucophelela ngokuya ngesisindo somzimba wakho futhi unikezwa ngabanakekeli noma odokotela abaqeqeshiwe abaqinisekisa kabili ukulinganisa ngaphambi kokufakwa ngakunye.
Uma ukhathazekile ngomthamo wakho noma uba nezimpawu ezingalindelekile ezinzima ngemuva kokwelashwa, xhumana nethimba lakho lezempilo ngokushesha. Bangahlola isimo sakho futhi banikeze ukunakekelwa okufanele. Indawo yezokwelapha elawulwayo lapho kunikezwa khona i-brentuximab inikeza izindlela eziningi zokuphepha ukuvimbela amaphutha okulinganisa.
Uma uphuthelwa ukufakwa kwe-brentuximab okuhleliwe, xhumana nethimba lakho lezempilo ngokushesha ngangokunokwenzeka ukuze uhlele kabusha. Ungazami ukuthi "ubambe" ngokuba nemithamo emibili eduze - lokhu kungakhuphula ingozi yakho yemiphumela engemihle ngaphandle kokuthuthukisa ukusebenza komuthi.
Udktela wakho uzoqoka indlela engcono kakhulu yokubuyela ohlelweni, okungase kuhlanganise ukulungisa umugqa wakho wesikhathi sokwelashwa kancane. Ukuphuthelwa umthamo owodwa ngokuvamile akuthinti kakhulu umphumela wakho wokwelashwa wonke, kodwa kubalulekile ukugcina isimiso esiqhubekayo ngangokunokwenzeka ukuze uthole imiphumela engcono kakhulu.
Kufanele uyeke kuphela ukwelashwa nge-brentuximab lapho udokotela wakho we-oncologist enquma ukuthi kufanelekile ukwenza kanjalo. Lesi sinqumo sisekelwe ekutheni i-lymphoma yakho isabela kahle kangakanani ekwelashweni, yimiphumela engemihle oyitholayo, kanye nemigomo yakho yokwelashwa iyonke. Ungalokothi uyeke i-brentuximab ngokwakho, ngisho noma uzizwa ungcono.
Udkt wakho uzohlola njalo intuthuko yakho ngezivivinyo zegazi kanye nokuskena okubonakalayo. Uma umdlavuza wakho uphendula kahle, ungase uqede inani elihleliwe lemijikelezo bese udlulela esigabeni sokuqapha. Uma uhlangabezana nemiphumela emibi ebalulekile, udokotela wakho angase alungise uhlelo lwakho lokwelapha noma acabange ngezindlela ezingezinye.
Ngokuvamile ungaqhubeka nokuhamba ngenkathi uthola i-brentuximab, kodwa kudinga ukuhlela nokuxhumana nethimba lakho lezempilo. Njengoba umuthi unikezwa njalo ngemva kwamaviki amathathu, kuzodingeka ukuthi uhlele uhambo lwakho ngokuqondene nokuqokwa kwakho kokufakwa komuthi. Udokotela wakho uzophinda afune ukuqinisekisa ukuthi unokufinyelela ekunakekelweni kwezempilo lapho uya khona uma kwenzeka uhlangabezana nanoma yimiphi imiphumela emibi.
Ngaphambi kokuhamba, xoxa ngezinhlelo zakho nodokotela wakho we-oncologist, ikakhulu uma uya phesheya noma ezindaweni ezikude. Bangase bakunikeze imibhalo yezokwelapha, balungise isimiso sakho sokwelashwa uma kudingeka, noma bakuxhumanise nabanikezeli bezempilo lapho uya khona. Kuhle futhi ukuhamba nohlu lwemithi yakho kanye nolwazi lokuxhumana nodokotela wakho.
Get clear medical guidance
on symptoms, medications, and lab reports.